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Abstract
Chromodomain, helicase, DNA binding 5 (CHD5) is a member of a subclass of the chromatin remodeling Swi/Snf
proteins and has recently been proposed as a tumor suppressor in a diverse range of human cancers. We analyzed
all 41 coding exons of CHD5 for somatic mutations in 123 primary ovarian cancers as well as 60 primary breast
cancers using high-resolution melt analysis. We also examined methylation of the CHD5 promoter in 48 ovarian
cancer samples by methylation-specific single-stranded conformation polymorphism and bisulfite sequencing. In
contrast to previous studies, no mutations were identified in the breast cancers, but somatic heterozygous mis-
sense mutations were identified in 3 of 123 ovarian cancers. We identified promoter methylation in 3 of 45 sam-
ples with normal CHD5 and in 2 of 3 samples with CHD5 mutation, suggesting these tumors may have biallelic
inactivation of CHD5. Hemizygous copy number loss at CHD5 occurred in 6 of 85 samples as assessed by single
nucleotide polymorphism array. Tumors with CHD5 mutation or methylation were more likely to have mutation of
KRAS or BRAF (P = .04). The aggregate frequency of CHD5 haploinsufficiency or inactivation is 16.2% in ovarian
cancer. Thus, CHD5may play a role as a tumor suppressor gene in ovarian cancer; however, it is likely that there is
another target of the frequent copy number neutral loss of heterozygosity observed at 1p36.
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Introduction
Chromodomain helicase DNA-binding 5, CHD5, is a member of a
subclass of the chromatin remodeling Swi/Snf proteins [1]. Proteins
within this subclass contain a Swi-Snf–like helicase and two chromo-
domain motifs. Members of this protein class have been shown to be
part of complexes that mediate chromatin remodeling and affect gene
transcription. Recently, Bagchi et al. [2] identified CHD5 as a puta-
tive tumor suppressor gene through functional analysis in a mouse
model. The model suggested that partial CHD5 deficiency compro-
mises p53 signaling and therefore abrogation of CHD5 function
might represent a generic mechanism for cancer development. Evi-
dence that CHD5 functions as a tumor suppressor in primary human
cancers has come principally from studies of neuroblastoma where
loss of the CHD5 locus on chromosome 1p36.3 is very common
[3]. CHD5 expression is consistently down-regulated in primary
neuroblastomas and cell lines [4] and may be affected by methylation
in neuroblastoma cell lines based on reexpression after treatment
with 5-azacytidine [5].
To date, the only evidence for a broader role of CHD5 in human
cancer has come from a genome-wide breast and colon cancer ge-
nome sequencing study where CHD5 was proposed as a “CAN-gene”
[6]. Heterozygous missense mutations were identified in 2 of 24
primary breast cancers and 1 of 11 cell lines. Loss of heterozygosity
Abbreviations: CN, copy number; HRM, high-resolutionmelt; LOH, loss of heterozygosity
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(LOH) at 1p is a common event in breast and ovarian cancers and
has been shown to correlate with poor survival [7,8], and therefore,
CHD5 is a logical candidate for the target of this LOH in these
cancer types. In this study, we have extended the range of tumors
where CHD5 plays a tumor suppressor role by demonstrating the
existence of somatic mutations and methylation in primary epithe-
lial ovarian cancers.
Materials and Methods
DNA Samples
One hundred and twenty-three primary ovarian cancers (56 se-
rous, 20 mucinous, 34 endometrioid, and 13 other) were obtained
from patients presenting to the hospitals in the south of England,
UK. DNA for mutation and methylation analyses was extracted from
whole fresh frozen specimens. Representative sections were hematox-
ylin and eosin–stained, and all tumors were assessed to contain >60%
tumor epithelium. Normal DNA was extracted from matching pe-
ripheral blood samples. Matching tumor and normal DNA from
60 primary breast cancers was provided by the Peter MacCallum
Cancer Centre tissue bank or by Dr Nick Hayward (Queensland
Institute for Medical Research, Brisbane, Australia). This study was
approved by institutional ethics committees. Before mutation screen-
ing, all stock DNA underwent whole genome amplification (WGA)
using the Repli-G Phi-mediated amplification system (Qiagen, Hilden,
Germany). To minimize the potential for generation of artifacts, WGA
was carried out in triplicate, using 25 ng of primary DNA, and the
products were pooled.
Mutation Analysis
The CHD5 gene was analyzed by high-resolution melt (HRM).
Exons 9, 13, 30, and 31 were amplified using previously reported
primer sequences [6]. For the remaining exons, primers were de-
signed to amplify each of the 41 exons and intron/exon boundaries
of the coding sequence in 156- to 477-bp fragments (median, 202 bp).
Primers were designed using the software packages ExonPrimer and
Primer3 [9]. Primer sequences and amplification conditions are listed
Figure 1. Somatic alterations in CHD5. (A) Somatic mutation in ovarian tumor IC318. The shift in exon 33 melting profile for IC318 is
indicated in red. (B) Somatic mutations in exon 29. The melting profiles are shown for tumor samples IC114 (purple) and IC139 (red). (C)
Normal and tumor sequence traces for exon 33 (left, arrow indicates C4992T heterozygous mutation) and exon 29 (center, arrow in-
dicates C4412T; and right, arrow indicates G4386A).
1254 CHD5 Analysis in Cancer Gorringe et al. Neoplasia Vol. 10, No. 11, 2008
in Table W1. Owing to their larger size, exons 5, 10, 11, 15, 23, and
38 were amplified in two overlapping fragments. TP53 (exons 5-8),
KRAS (amino acids 1-36), and BRAF (V600E) were analyzed previ-
ously [10] or using HRM (Table W1). High-resolution melt was car-
ried out in duplicate using polymerase chain reaction (PCR) products
amplified from 10 ng of WGA template DNA. Gene scanning anal-
yses were carried out for each exon using the LightCycler 480 (Roche
Diagnostics, Mannheim, Germany). Samples with replicated shifts in
the DNA melt curves were reamplified, and the PCR product was
directly sequenced using BigDye Terminator v3.1 (Applied Biosys-
tems, Foster City, CA). Somatic alterations were confirmed by rese-
quencing from the unamplified stock tumor DNA and the matching
normal DNA. Polymerase chain reaction products for sequencing
were purified by nucleotide removal columns or agarose gel extrac-
tion (Qiagen).
Analysis of CpG Island Methylation by Methylation-Specific
Single-Stranded Conformation Polymorphism and
Bisulfite Sequencing
The CHD5 CpG island was identified in University of California
Santa Cruz genome browser (genome.ucsc.edu) and methylation-
specific single-stranded conformation polymorphism (MS-SSCP) PCR
primers designed from genomic DNA sequence using MethPrimer
(www.urogene.org/methprimer) [11]. Both forward and reverse oligo-
nucleotide primers were fluorescently labeled with either FAM or
HEX. Primer sequences are listed in Table W1.
DNA samples were treated with bisulfite using the MethylEasy
Kit (Human Genetic Signatures, Sydney, Australia) following the
manufacturer’s instructions. After PCR amplification, products were
analyzed by SSCP using the ABI 3130 Genetic Analyzer (Applied
Biosystems) as described previously [12]. Samples showing a shift
in mobility were sequenced, whereas the remainder were considered
normal. Twenty-four samples were sequenced without performing
SSCP. SssI methylase–treated normal DNA was used as a positive
control for CpG island methylation. This enzyme methylates all
CpGs before bisulfite treatment. Polymerase chain reaction products
for sequencing were reamplified using unlabeled primers and purified
by nucleotide removal columns (Qiagen). Purified PCR products
were sequenced in both forward and reverse directions using BigDye
Terminator v3.1 (Applied Biosystems). Full methylation at a par-
ticular CpG was defined as follows: >60% of the average bisulfite
sequencing signal was “C,” whereas partial methylation was 40%
to 60%. “Methylation-positive” was defined as at least 18 of the
35 CpGs within the PCR product showing full or partial methyla-
tion. “Partial methylation” was defined as at least 6 of 35 CpGs
showing full or partial methylation.
Real-time Reverse Transcription Quantitative PCR
RNA was extracted from cell lines or from microdissected tumors
using the miRVana RNA isolation kit according to the manufac-
turer’s instructions (Ambion, Austin, TX). Samples were reverse tran-
scribed and amplified according to the Affymetrix Gene 1.0ST array
protocol (Affymetrix, Santa Clara, CA) and 30 ng of the ssDNA was
used per 10-μl PCR. This RNA amplification step was performed to
ensure sufficient template in the reaction for reproducible quantita-
tion. Primers were designed to CHD5 and a control gene PGK1
(Table W1), and PCR was performed with the SYBRgreen QPCR
mix (ThermoScientific, Waltham, MA) and the LightCycler 480
(Roche Diagnostics, Mannheim, Germany). Cp (“crossing point”)
was calculated using the second derivative maximum method. The
relative levels of expression of CHD5 and PGK1 were calculated
using a normal ovarian surface epithelial cell line (HOSE) RNA as
a control standard curve.
Single Nucleotide Polymorphism Array Analysis
Affymetrix single nucleotide polymorphism (SNP) 500K and SNP
6.0 Mapping arrays were performed on unamplified DNA obtained
from microdissected fresh frozen tissue sections, and the data were an-
alyzed using Partek Genomics Suite (Partek, St Louis, MO), GTYPE
(Affymetrix), and CNAG software as described previously [13].
Loss of heterozygosity was determined by examination of the allele-
specific copy number (CN) ratios in CNAG [14,15].
Results and Discussion
Mutation Analysis of CHD5 Using HRM
High-resolution melt analysis covering all of the CHD5 protein
coding sequence and intron/exon boundaries (a total of 47 PCR
products) was carried out on DNA from 123 primary ovarian cancers
and 60 primary breast cancers. No mutations were identified in any
of the breast tumors, but three ovarian tumors were shown to harbor
somatic heterozygous missense alterations: C4992T (Ser1631Phe),
C4412T (Arg1438Cys) and G4386A (Arg1429Gln) (Figure 1 and
Table 1). The somatic nature of the mutations was confirmed by se-
quencing matching normal lymphocyte DNA. The Ser1631Phe and
Arg1429Gln mutations were identified in grade 3, stage III serous type
tumors, and the Arg1438Cys mutation was identified in a grade 2
stage IA endometrioid tumor. Analysis of the effect of the missense
mutations on protein structure and function was performed using
Table 1. CHD5 Coding Sequence Alterations.
Exon Sequence
Alteration
Codon Amino Acid Heterozygote Frequency
Breast Cancer Ovarian Cancer
Somatic mutations
29 G4386A CGG to CAG Arg1429Gln 0/60 1/121
29 C4412T CGC to TGC Arg1438Cys 0/60 1/121
33 C4992T TCC to TTC Ser1631Phe 0/60 1/123
Polymorphisms
4* G529C CTG to CTC Leu143Leu 7/60 13/123
5 G679C CGG to CGC Arg193Arg 0/60 1/122
6 C876G TCC to TGC Ser259Cys 1/60 0/123
7* C1003T TTC to TTT Phe301Phe 27/60 41/123
7 G1014A AGC to AAC Ser305Asn 1/60 0/123
8* A1204G GTA to GTG Val368Val 22/60 39/123
9 C1378A GGC to GGA Gly426Gly 2/60 0/123
10 T1666C CAT to CAC His521His 0/60 1/123
11 C1768T TAC to TAT Tyr556Tyr 1/60 0/123
12* C1957T TAC to TAT Tyr619Tyr 9/60 15/123
14 G2200A CTG to CTA Leu700Leu 1/60 0/123
15* C2479T AAC to AAT Asn793Asn 13/60 21/123
16* T2593C ATT to ATC Ile831Ile 24/60 51/123
18 G2878A CCG to CCA Pro926Pro 0/60 1/123
22* G3436A GCG to GCA Ala1112Ala 9/60 13/123
28 C4336T CTC to CTT Leu1412Leu 3/60 4/123
31* T4715C TCG to CCG Ser1539Pro 30/60 53/121
32 G4828T ATG to ATT Met1576Ile 1/60 0/123
34 C5089T TCC to TCT Ser1663Ser 0/60 1/123
35 C5170T GAC to GAT Asp1690Asp 0/65 1/123
36 C5344T ATC to ATT Ile1748Ile 0/60 1/123
36 C5349T ACG to ATG Thr1750Met 1/60 0/123
Asterisks indicate previously identified polymorphisms.
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three different prediction algorithms: PolyPhen [16], SIFT [17], and
PMUT [18]. All three mutations were predicted to affect protein
function by at least two of the prediction algorithms (Table W2).
The absence of somatic mutations in 60 primary breast cancers is
at variance with the 9% mutation frequency (2/24 primary breast
cancers and 1/11 breast cancer cell lines) reported by Sjöblom et al.
[6] in a genome-wide sequencing screen. It is unlikely that the ab-
sence of somatic mutations in the breast cancers is caused by lack
of sensitivity of HRM, which has a growing reputation as a highly
sensitive mutation detection technique [19,20]. We were able to de-
tect a large number of polymorphisms located in the coding se-
quence (22 variants) or within the intron sequences (24 variants;
Table 1, Table W3, and Figure W1). In our hands, sequence var-
iants were readily detectable even in samples where there was nor-
mal DNA contamination or where the variant was present at a low
abundance due to LOH (Figure W1). In addition, we were able to
detect compound polymorphisms, in which a sample with a com-
mon polymorphism also had a less frequent polymorphism present
(Figure W1). The distribution of histologic subtypes, grade, and
stage of tumors examined in our study and by Sjöblom et al. [6]
was similar, suggesting that the discrepancy in tumor mutation fre-
quency might be due to chance given that it was not statistically
significant (Fisher’s exact test, P = .079). Our study does suggest
that the frequency of CHD5 mutations in breast cancers might
be lower than the 9% reported previously and highlights the im-
portance of following up leads from genome-wide sequencing
screens with independent sample sets. This is the first study of so-
matic mutation and methylation of CHD5 in ovarian cancer, and
the data indicate that CHD5 has a tumor suppressor role in a sub-
set of cases. Interestingly, all three mutations were detected in tu-
mors that were heterozygous across the CHD5 locus.
The CHD5 Promoter Is Sometimes Methylated in Primary
Ovarian Cancer
Because the expression of tumor suppressor genes is sometimes re-
duced as a consequence of promoter hypermethylation, we examined
the promoter of CHD5 in ovarian tumors. CHD5 has a predicted
CpG island spanning 1577 bp, beginning 631 bp upstream of the
transcription start site and comprising 180 CpGs (Figure 2). Meth-
ylation was detected in three of six ovarian cancer cell lines, with at
least 80% of CpGs fully methylated as determined by bisulfite se-
quencing (Figure 2). Primary ovarian cancers showed less frequent
methylation, with 5 of 48 methylated and 2 of 48 partially methyl-
ated. We verified that methylation was not the result of contamina-
tion of tumor by fibroblasts or lymphocytes by bisulfite sequencing
the CHD5 promoter in one cancer-associated fibroblast cell line, one
microdissected stromal DNA sample, and one normal lymphocyte
DNA sample. None of these samples showed any methylation. Pro-
moter methylation was more frequent and extensive in the cell
lines than the primary tumors, suggesting that methylation of the
CHD5 promoter may be common in the transition from primary
tumor to cell line. Notably, two methylated samples (IC114T and
IC139T) also carried somatic mutations (Table 2). We carried out
real-time reverse transcription PCR for CHD5 on samples for which
sufficient RNA could be extracted. Samples with methylated pro-
moters showed uniformly low levels of expression (Figure 2). Un-
methylated samples showed variable expression levels, suggesting
that there may be other mechanisms by which CHD5 expression is
regulated. The three CHD5 wild type cancers with a high level of
promoter methylation comprised a mixed mullerian tumor and
two mucinous tumors.
Copy Number Loss Is an Alternate Mechanism of CHD5 in
Ovarian Cancer
A mouse model of CHD5 deficiency suggested that haploinsuffi-
ciency of CHD5 may contribute to cancer progression rather than a
“two-hit” mechanism expected of a classic tumor suppressor [2]. In
light of this, we considered the possibility that CHD5 might be
the target of CN loss, which would be consistent with (but not
proof of ) targeted haploinsufficiency of CHD5. We evaluated 85 pri-
mary ovarian cancers (56 with known CHD5 mutation status) using
Affymetrix 500K or 6.0 SNP Mapping arrays [13]. These arrays are
able to detect both CN losses and CN neutral LOH. We detected
Figure 2. CHD5 promoter methylation in ovarian cancer. (A) University of California Santa Cruz genome browser view of the CHD5 gene,
which is located on the reverse strand (genome.ucsc.edu). The CHD5 promoter contains a strong CpG island as demonstrated in the
MethPrimer (www.urogene.org/methprimer) output below. The location of the primers used for SSCP and sequencing is shown (F1 and
R1). (B) Sequence electropherogram traces from primary ovarian tumors showing methylated and unmethylated samples. (C) Summary
of bisulfite sequencing from cell lines and primary tumors showing methylation. CpG dinucleotide number within the PCR product listed
across the top from distal to proximal relative to transcription start site. Black, fully methylated (>60%); gray, partial methylation (40-60%);
white, <40% methylation. An additional 15 tumors were sequenced that showed no methylation. Samples with a CHD5 mutation are
shown in bold. Sample IC139T data are based on cloning the PCR product and sequencing five clones as the direct sequencing was
poor. (D) Quantitative PCR of CHD5. The expression level of CHD5 is shown as a ratio relative to the control gene. An asterisk indicates a
CHD5-mutated sample. SEs are shown.
Table 2. Summary of CHD5 and Pathway Interactions.
Sample Subtype CHD5 KRAS Mut KRAS CN BRAF Mut TP53 Mut
IC114 Endometrioid Arg1438Cys,
methylation
wt — wt wt
IC139 Serous Arg1429Gln,
methylation
wt — V600E wt
IC318 Serous Ser1631Phe wt Gain wt wt
IC197 MMT Methylation wt — wt wt
IC50T Mucinous Methylation wt n V600E wt
IC80T Mucinous Methylation G12V n wt wt
IC281 Serous CN loss wt n wt —
IC288 Serous CN loss wt n wt —
IC382 Serous CN loss wt n wt —
IC594 Endometrioid CN loss wt n wt wt
P0566 Mixed CN loss wt n wt wt
P5338 Serous CN loss — Gain — —
IC022 Serous CN gain wt Gain wt Y220C
IC135 Serous CN gain wt n wt del156-159
IC434 Endometrioid CN gain wt n wt wt
(—) indicates not done; n, normal CN; wt, wild type.
Neoplasia Vol. 10, No. 11, 2008 CHD5 Analysis in Cancer Gorringe et al. 1257
CHD5 CN loss (defined as a log2 ratio of <−0.3) [13] in 6 (7%) and
gain (log2 ratio of >0.3) in 3 (3.5%) of 85 ovarian tumors (Fig-
ure W2). The CHD5 region showed LOH (both CN neutral and
CN loss) in 30 samples (35%); however, LOH at any locus on chro-
mosome 1p was detected in 39 samples (46%) and suggests that an-
other gene(s) is the target of LOH on chromosome 1p (Figure W3).
The mouse and in vitro models of CHD5 gene dosage suggested
that CHD5 acts within the p53 pathway, with loss of CHD5 result-
ing in reduced expression of p53 target genes. CHD5 loss also inter-
acted with KRAS to promote transformation. We therefore looked to
see whether CHD5 mutation or methylation coincided with altera-
tions in the KRAS pathway or TP53 mutation. Interestingly, three of
six of the CHD5mutation- or methylation-affected samples had alter-
ation in the KRAS pathway, one by KRASmutation and two by BRAF
mutation (P = .04, Fisher’s exact test), whereas none had mutation of
TP53 (Table 2). However, this association was not evident among the
samples showing CHD5 CN loss only with none from five samples
having either KRAS or BRAF mutation (P = 1, Fisher’s exact test).
Altogether, when mutation (2.4%) and methylation (without mu-
tation, 6.7%) are combined, CHD5 is affected in 9.1% of ovarian
cancers, which is extended to 16.2% if cases with CN loss (7.1%)
are included. However, the consequence of heterozygous CN loss
at CHD5 in ovarian cancer is not clear, given that two of three
samples with mutation also showed methylation, suggesting biallelic
inactivation rather than haploinsufficiency. Our study supports the
contention that CHD5 is a tumor suppressor gene in a subset of
ovarian tumors. The disparity between the frequency of CHD5 alter-
ation (16%) and LOH at 1p (46%) strongly suggests another tumor
suppressor gene in the region. CHD5 mutation and/or methylation,
but not CN loss, may co-operate with the KRAS pathway in tumor-
igenesis; however, the number of samples is small and this result will
require future validation. The lack of CHD5 mutations in the breast
cancer samples screened in this study is in contrast to the 9% fre-
quency reported previously [6]. Because the difference in mutation
frequencies is not statistically significant, it is likely to be due to
chance, although a contribution of the screening methodologies used
cannot be excluded.
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Table W1. Oligonucleotide Primer Sequences.
Primer Name Primer Sequence (5′–3′) Annealing Temperature (°C) Primer Concentration (nM) Buffer* Length (bp)
CHD5Exon1Fnew CAGCGCACGGGTTAAGG 65 300 Q 161
CHD5Exon1Rnew CGCTCACCTGACATCTCGT
CHD5Exon2F AGTAACTGCTGCCACCTTCTG 62 200 Q 217
CHD5Exon2R CAGATGCAGCCACAACCC
CHD5Exon3F CTCTGTTGCCCTCACTGTCC 65 200 Q 287
CHD5Exon3R CATACAGGCAAGAGGCTCAG
CHD5Exon4F CAACTCTACCTCTGGCCTGG 58 200 SM 202
CHD5Exon4R GGTACCACCAGAGGATGTGC
CHD5Exon5_1F TCTCATCTCACCTGGCCTTG 60 300 SM 209
CHD5Exon5_1R GATGGTGACCGTCTCTACAGC
CHD5Exon5_2F AGTTCAGCGCCAACAACC 58 200 Q 195
CHD5Exon5_2R GACTAGGTGCCCACCCAAC
CHD5Exon6F TGGTTGGCTATCATCACTGC 58 200 Q 195
CHD5Exon6R ATGCAAATGCACACACACG
CHD5Exon7F CTGGGATCACAGGACCC 56 200 Q 186
CHD5Exon7R GCCAAGAACTCTCTGGAAGG
CHD5Exon8F AGGACTTCCATGACTGCCTC 62 300 Q 272
CHD5Exon8R CCAAATGAGGGCACAGGG
CHD5Exon9newF CCCTGTGCCCTCATTTGG 58 300 Q + QS 477
CHD5Exon9newR CTTTGCGGGATCGGCTAC
CHD5Exon10_1F CACCTTGGGGACCCTTC 56 200 SM 193
CHD5Exon10_1R TGCCCACTTGACAAAGAACTC
CHD5Exon10_2F CCTTCATGGTGGGGCTG 65 200 Q 171
CHD5Exon10_2R TAGCACAGCCACCCTCCC
CHD5Exon11_1F CCCTTCTGTGACTTTGTGCC 54 100 Q 184
CHD5Exon11_1R GCTCCTCCATCTTGGCATAG
CHD5Exon11_2F CTACGGCTCTGGGGATGAAG 58 200 Q 196
CHD5Exon11_2R AGAAGCTGACGTGGCCC
CHD5Exon12F GCGACCCACATCTGTTCAC 68 300 SM 197
CHD5Exon12R CAGCCTGTGCCTAGCAGC
CHD5Exon13Fnew CCTTGCTCACCTGCCTCCAAT 58 300 Q 216
CHD5Exon13Rnew CCCCTGCACATTCAAGTCTGAG
CHD5Exon14F CGTGTCTGAACCGCTGC 60 200 Q 262
CHD5Exon14R AGGACCAGCCACCCCTC
CHD5Exon15_1F AGGTGGTCTCACGGCATC 54 100 Q 176
CHD5Exon15_1R TTCTCCCGAATCACCGAG
CHD5Exon15_2F GAACGCGAGTTTGAGATGTG 54 100 Q 184
CHD5Exon15_2R GGGCCTTCCTACCGTCC
CHD5Exon16F TGTGATCCGCTCTGCTCC 58 300 SM 227
CHD5Exon16R GGAAGCTCTGGGGTCTGG
CHD5Exon17F CTGACAGGCCCCACTCTC 62 100 Q 185
CHD5Exon17R ACCACCACCTCCCTAGCC
CHD5Exon18F CTGGCTGTTATCCCAGCTT 60 300 SM 274
CHD5Exon18R GAATCGACCCAGGAGACCA
CHD5Exon19F GTCTGACCCAGCCTGCC 62 100 Q 224
CHD5Exon19R ATGGCGGTCATGGAGAAG
CHD5Exon20F CCTTTGGTGCAGAGTCAGAG 58 200 Q 261
CHD5Exon20R ATCAGGGCAGGATGCTCTC
CHD5Exon21F CCTTGCTCCTTGGCAGTTC 56 200 Q 191
CHD5Exon21R AATCAGAACCCTTGGGCAG
CHD5Exon22F CCCCAAACACTCCCATCTG 60 300 Q 233
CHD5Exon22R AAGGACAGAACCTGCCTGAG
CHD5Exon23_1F GAGCCACGGGTGCTGAG 60 300 SM 200
CHD5Exon23_1R GTCATGGACCCCGACTTG
CHD5Exon23_2F AGGAGCGCATCACGCAG 65 200 Q + M 183
CHD5Exon23_2R CCACGCTCCCTCGGAAC
CHD5Exon24F CTGCACCAGTGCTTTCCTTC 60 300 SM 188
CHD5Exon24R ACCTGGTCGGAGGAGGAG
CHD5Exon25F GTCCTCACACTGCATTTGCC 68 300 Q 283
CHD5Exon25R TGGAAGGCGTGGACACAG
CHD5Exon26F GGAGGGCAGAGATGGCTC 65 200 Q + M 260
CHD5Exon26R GTGAGGGGCACCAGTCC
CHD5Exon27Fnew GGAAGTATGTGGGCCATTGTC 58 300 SM 352
CHD5Exon27Rnew GAGCCCAGAGATTCCTGATCC
CHD5Exon28F CTCCCACCTGAGGAACTGTG 62 200 Q 167
CHD5Exon28R GAAGCAGGGGCAGAAAGAG
CHD5Exon29F CTGTCCTGGGCTCATACTCC 68 300 SM 222
CHD5Exon29R CTACTCAGGGGCAGGTGGTC
CHD5Exon30Fnew GATGGTTGAAGATCAGCCAGG 58 300 Q + QS 334
CHD5Exon30Rnew CTCTGACCACTGACCCACAAG
CHD5Exon31Fnew CAAGCCTGTGACACTTTCAGC 58 300 Q 358
CHD5Exon31Rnew TCTGTGGGATTGTGGGTTAGAC
Table W1. (continued )
Primer Name Primer Sequence (5′–3′) Annealing Temperature (°C) Primer Concentration (nM) Buffer* Length (bp)
CHD5Exon32F ACCTGTCTCAGCTCTTTCCC 65 200 Q 156
CHD5Exon32R CACCCCACACACACCACAG
CHD5Exon33F CCCAGGCCTTGTAGTTCTCC 62 200 Q 211
CHD5Exon33R AGACATGGCACTGGGGTG
CHD5Exon34F GTTTTCTGGGACCCCACC 62 100 Q 172
CHD5Exon34R GGGGCACAGGTAGAGAACAC
CHD5Exon35F GATGGATGAATGAATGTGATCTG 54 100 Q 211
CHD5Exon35R AGGAAGCCTCAGCTCTCTGC
CHD5Exon36F CACTTCTCACCCTGCTCACC 65 300 SM 187
CHD5Exon36R GAACGGGCAAGTCCCTG
CHD5Exon37F CAGGTTTGCCCTTAATGGTG 58 200 Q 218
CHD5Exon37R CTCCTGACACCGTCCCTC
CHD5Exon38_1F ACGGAGGGTAGCCATTCAG 54 200 Q 182
CHD5Exon38_1R GGCGAGGCACTCCACTTC
CHD5Exon38_2F ACCTGAACATGACGCAGGAC 56 100 Q 227
CHD5Exon38_2R GCCCTCATCTACAGCCAAGAG
CHD5Exon39F CATCCCTGCATCCTACCATC 65 300 Q 266
CHD5Exon39R ACCCAGCCTCCACCCAG
CHD5Exon40F CCACCTGTGAAGCTGAGTCC 58 100 Q 184
CHD5Exon40R CACCCGTGTGCATGCTG
CHD5Exon41F CTATGTGACCGGTAGGTGCC 58 300 Q 185
CHD5Exon41R CAGCAGCCCTCACCTCAG
KRAS 1-36F GGCCTGCTGAAAATGACTGA 65 100 SM 162
KRAS 1-36R GTCCTGCACCAGTAATATGC
P53 Exon5F CACTTGTGCCCTGACTTTCA 60 100 SM 267
P53 Exon5R AACCAGCCCTGTCGTCTCT
P53 Exon6F CAGGCCTCTGATTCCTCACT 60 100 SM 185
P53 Exon6R CTTAACCCCTCCTCCCAGAG
P53 Exon7F CCTGCTTGCCACAGGTCT 60 100 SM 201
P53 Exon7R GTGTGCAGGGTGGCAAGT
P53 Exon8F TTTCCTTACTGCCTCTTGCTTC 60 100 SM 227
P53 Exon8R TAACTGCACCCTTGGTCTCC
BRAF V600E_F CCTAAACTCTTCATAATGCTTGCTC 65 100 SM 189
BRAF V600E_R CCACAAAATGGATCCAGACA
CHD5 Meth F GTTGTTTTGAAGATTTTGTTTT 58 100 Q + M 321
CHD5 Meth R CTAATTACTATAACAACCCCATCCC
CHD5 QPCR F CTCAACGAGCCCTTCAAGTC 60 300 S 97
CHD5 QPCR R CTGCTCCAGCAGCTTAAACC
PGK1 F ATTAGCCGAGCCAGCCAAAATAG 60 50 S 94
PGK1 R TCATCAAAAACCCACCAGCCTTCT
*Buffer: Q = Qiagen Hotstar Taq with 1.5 mMMgCl2; Q + M = Qiagen Hotstar Taq with 3.5 mMMgCl2; Q + QS = Qiagen Hotstar Taq with 1.5 mMMgCl2 and 1× “Q” solution; S, SYBR green mix
from ThermoScientific; SM = Roche ScanMaster mix with 2.5 mM MgCl2.
Table W2. Predicted Effect of Amino Acid Missense Substitutions.
Sequence Change PolyPhen* SIFT† PMUT‡ Consensus
This study
Arg1429Gln 1.892 0.00 0.34/3 Pathogenic
Arg1438Cys 2.792 0.00 0.81/6 Pathogenic
Ser1631Phe 1.666 0.05 0.67/3 Pathogenic
Previous mutations§
Val45Met 0.675 0.14 0.04/9 Neutral
Asp119Met 2.025 0.04£ 0.36/2 Pathogenic
Arg667Gly 1.321 0.26 0.49/0 Neutral
Samples in bold were scored as possibly pathogenic.
*PolyPhen: scores increase from zero with a higher score being more likely to be pathogenic.
†SIFT: scores ≤0.05 classed as pathogenic.
‡PMUT: first score increases from zero, pathogenic if >0.5, second score measures reliability from 0
being unreliable to 9 being very reliable.
§From Sjöblom et al. [6].
£SIFT flagged this change as unreliable because only one other sequence had this amino acid
for comparison.
Table W3. Intron Polymorphisms.
Intron* Sequence Alteration Frequency
Breast Cancer Ovarian Cancer
2 +30 T/G 5/60 4/123
3 +33 C/A 10/60 13/123
4 +33 C/T 0/60 1/123
6 +18 T/C 0/60 1/123
8* +40 C/A 7/60 9/123
8* +46 C/A 1/60 0/123
14 +10 C/T 0/60 1/123
15 +10 C/G 0/60 2/123
15*,† −18 T/C 24/60 51/123
15*,† −26 T/C 24/60 51/123
18 +21 G/A 2/60 0/123
18 +27 G/A 1/60 0/123
19 +13 G/A 0/60 1/123
19* −28 A/C 20/60 25/121
22* +49 G/A 22/60 28/123
24* +13 C/T 24/60 39/123
24 +27 G/T 0/60 1/123
25* +61 delC 2/60 0/123
27 +69 C/T 1/59 0/123
30* −25 T/C 35/58 71/119
34 −5 G/A 2/60 1/123
37 +29 delC 30/60 54/123
39 +29 G/A 0/60 1/123
39 +41 G/A 0/60 1/123
*Asterisks indicate previously identified polymorphisms.
†The two-intron 15 polymorphisms are tightly linked with the exon 16 T2593C polymorphism.
Figure W1. Sensitivity of HRM to detect sequence alterations. (A) Exon 3 polymorphism difference plot showing the polymorphism shift in
red and a tumor sample, IC323, which has LOH of the polymorphism in orange. (B) Sequence traces with the normal IC323 sequence
showing intron 3+33C/A polymorphismand the tumor IC323 sequence showing LOHof the “A” allele (filled arrowhead). (C) TheCNneutral
LOHwas confirmed by the SNP array data. (D) Intron 24 compound polymorphism. In red are samples heterozygous for the single intron 24
+13C/T polymorphism, whereas in green (open arrow) is the sample heterozygous for both +13C/T and +27G/T polymorphisms.
Figure W2. SNP array data for chromosome 1p. Example data from four primary ovarian tumors, two with CN loss and LOH at CHD5 and
two with CN gain and allelic imbalance (AI) at CHD5. Blue line is a 10-point moving average, with the scale indicating linear CN. Below is
the allele-specific CN for the most intense (red line) and least intense (green line) alleles.
Figure W3. Chromosome 1p LOH in ovarian cancer samples. SNP array data from p-terminus at left to 1p34.2 at right. Bar indicates
presence of LOH, color coded to histologic subtype as indicated by the legend. The location of CHD5, affected in 30 (35%) of 85 sam-
ples, is shown.
